Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiajun Fu

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Hepatology (Baltimore, Md.)|June 16, 2021
TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion InjuryJunjie Zhou, Manli Hu, Meiling He, et al.
The Journal of Clinical Investigation|January 11, 2024
TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthaseSuowen Xu, Xiumei Wu, Sichen Wang, et al.
Gut|May 21, 2026
Blocking MOXD1-derived ACOX1 peroxisome trafficking suppresses metabolic dysfunction-associated steatohepatitisMei Li, Jinquan Zhang, Yunfan Yang, et al.
Science Translational Medicine|February 14, 2024
Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progressionLan Bai, Weiyi Qu, Xu Cheng, et al.
The Journal of Clinical Investigation|September 2, 2025
Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction-associated steatohepatitisXiao-Jing Zhang, Jiajun Fu, Xu Cheng, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Hepatology (Baltimore, Md.)|June 16, 2021
TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion InjuryJunjie Zhou, Manli Hu, Meiling He, et al.
The Journal of Clinical Investigation|January 11, 2024
TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthaseSuowen Xu, Xiumei Wu, Sichen Wang, et al.
Gut|May 21, 2026
Blocking MOXD1-derived ACOX1 peroxisome trafficking suppresses metabolic dysfunction-associated steatohepatitisMei Li, Jinquan Zhang, Yunfan Yang, et al.
Science Translational Medicine|February 14, 2024
Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progressionLan Bai, Weiyi Qu, Xu Cheng, et al.
The Journal of Clinical Investigation|September 2, 2025
Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction-associated steatohepatitisXiao-Jing Zhang, Jiajun Fu, Xu Cheng, et al.
Pageof 8